Britta Jacobsen, PhD

Publications

• Jacobsen BM, Schittone SA, Richer JK, and Horwitz KB (2005) Progesterone Independent Effects of Human Progesterone Receptors (PR) in Estrogen Receptor Positive Breast Cancer: PR isoform-specific Gene Regulation and Tumor Biology. Mol Endocinology 19(3):574-587.
• Ghatge RP, Jacobsen BM, Schittone SA, and Horwitz KB (2005) Medroxyprogesterone Acetate: A Dual Function Hormone that at Physiologic doses is both a Progestin and Androgen in Human Breast Cancer Cells. Breast Cancer Research 7(6): R1036-R1050.
• Bray JD, Jelinsky S, Ghatge R, Bray JA, Tunkey C, Saraf K, Jacobsen BM, Richer JK, Brown EL, Winneker RC, Horwitz KB, Lyttle CR. Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells. J Steroid Biochem Mol Biol. 2005 Dec;97(4):328-41. Epub 2005 Sep 12.
• Jacobsen BM, Harrell JC, Jedlicka P, Borges VF, Varella-Garcia M, Horwitz KB. Spontaneous fusion with, and transformation of mouse stroma by, malignant human breast cancer epithelium. Cancer Res. 2006 Aug 15;66(16):8274-9. PMID: 16912208 [PubMed - in process]
• Carol A. Lange, Carol A. Sartorius , Hany Abdel-Hafiz, Monique A. Spillman, Kathryn B. Horwitz and Britta M. Jacobsen Progesterone Receptor Action: Translating Studies in Breast Cancer Models to Clinical Insights Innovative Endocrinology of Cancer. Edited by: Lev M. Berstein and Richard J. Santen ISBN: 978-0-387-78817-3
• J Chuck Harrell, Carol A. Sartorius, Wendy W. Dye, Britta M. Jacobsen and Kathryn B. Horwitz. ZsGreen Labeling of Breast Cancer Cells to Visualize Metastasis. Clontechniques: April, 2007, p. 1-3.
• Progesterone receptor action: translating studies in breast cancer models to clinical insights. Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM. Adv Exp Med Biol. 2008;630:94-111.
• Britta M. Jacobsen, Melanie Badtke, Purevsuren Jambal, Kathryn B Horwitz. BCK4 cells are a new model of mucinous human breast cancer. AACR Annunal Meeting, 2009; #287.
• Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the Androgen Receptor in Breast Cancer and Preclinical Analysis of Enzalutamide. Breast Cancer Res. 2014 Jan 22;16(1):R7. [Epub ahead of print] PubMed PMID: 24451109
• Harvell DM, Kim J, O'Brien J, Tan AC, Borges VF, Schedin P, Jacobsen BM, Horwitz KB. Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. Horm Cancer. 2013 Jun;4(3):140-53. PubMed PMID: 23479404
• Melanie M. Badtke, Purevsuren Jambal, Wendy Dye, Kathryn B. Horwitz, Britta M. Jacobsen. Progesterone Receptors Attenuate Taxane-induced Cell Death in Breast Cancer Cells by Altering Spindle Assembly Checkpoint Genes. AACR Annual Meeting 2009, #813
• Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Breast Cancer Res Treat. 2013 Jan;137(2):431-48. PubMed PMID: 23247610
• Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Oncogene. 2013 May 16;32(20):2555-64. PubMed PMID: 22751119
• Melanie M. Badtke, Purevsuren Jambal, Kathryn B. Horwitz and Britta M. Jacobsen. Progesterone Receptors (PR) Protect Breast Cancers from Killing by Taxanes. Department of Defense Era of Hope Meeting, 2008; #P28-5.
• Pinto MP, Dye WW, Jacobsen BM, Horwitz KB. Malignant stroma increases luminal breast cancer cell proliferation and angiogenesis through platelet-derived growth factor signaling. BMC Cancer. 2014 Oct 1;14:735. PubMed PMID: 25274034
• Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2014 Sep 22;0. [Epub ahead of print] PubMed PMID: 25241899
• Mauricio Pinto, Britta M. Jacobsen, Kathryn B. Horwitz. Malignant stromal cells enhance proliferation and aggressiveness of breast cancer cells by producing VEGF and TIMP-1. AACR Annual Meeting, 2009; #2329
• Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014 Jan 22;16(1):R7. PubMed PMID: 24451109
• Jacobsen BM, Jambal P, Schittone SA and Horwitz KB (2009) ALU-like repeats in promoters are position dependent co-response elements (coRE) that enhance or repress transcription by dimeric and monomeric progesterone receptors. Molecular Endocrinology 2009 Jul;23(7):989-1000. Epub 2009 Apr 16.
• Pinto MP, Badtke MM, Dye W, Dudevoir M, Jacobsen BM, Horwitz KB. Vascular endothelial growth factor secreted by activated stroma enhances angiogenesis and hormone independent growth of estrogen receptor positive breast cancer. Cancer Research (Accepted)January 25th, 2010.
• Pinto MP, Jacobsen BM, Horwitz KB. Malignant stromal cells enhance proliferation and aggressiveness of breast cancer cells by secreting VEGF and TIMP-1. 2009. AACR Breast cancer meeting, San Diego CA, Abstract #2329.
• Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, Polo ML, Gorostiaga MA, Jacobsen B, Molinolo A, Novaro V, Lanari C. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer. 2014 Nov 1. [Epub ahead of print] PubMed PMID: 25363551
• Jambal P, Badtke M, Jedlicka P, Borges V, Horwitz KB, Jacobsen BM. Estrogen Induces a Histologic Switch to Invasive Ductal Carcinomas in a New Model of Mucinous Human Breast Cancer. NUCLEAR RECEPTOR KEYSTONE MEETING, Keystone, Colorado. March 21st-26th, 2010, #220
• Spillman MA, Manning NG, Dye W, Harvell ME, Jacobsen BM, Horwitz KB. Estrogen Replacement Therapy Induces a Unique Gene Expression Pattern in Ovarian Cancer. NUCLEAR RECEPTOR KEYSTONE MEETING, Keystone, Colorado. March 21st-26th, 2010 #334.
• Badtke MM, Jambal P, Dye W, Spillman MA, Post MD, Horwitz KB, Jacobsen BM. Progesterone Receptors Attenuate Taxane-induced Cell Death in Breast Cancer Cells by Altering Spindle Assembly Checkpoint Genes. 2011. Breast Cancer Research and Treatment DOI;10.1007/s10549-011-1399-0
• Spillman MA, Manning NG, Dye WW, Sartorius CA, Post MD, Harrell JC, Jacobsen BM, Horwitz KB. Tissue Specific Pathways for Estrogen Regulation of Ovarian Cancer Growth and Metastasis. Cancer Res. 2010 Nov 1;70(21):8927-36. Epub 2010 Oct 19.
• Barton VN, D'Amato NC, Gordon MA, Lind HT, Spoelstra NS, Babbs BL, Heinz RE, Elias A, Jedlicka P, Jacobsen BM, Richer JK. Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo. Mol Cancer Ther. 2015 Mar;14(3):769-78. PubMed PMID: 25713333
• Wargon V, Riggio M, Giulianelli S, Sequeira GR, Rojas P, May M, Polo ML, Gorostiaga MA, Jacobsen B, Molinolo A, Novaro V, Lanari C. Progestin and antiprogestin responsiveness in breast cancer is driven by the PRA/PRB ratio via AIB1 or SMRT recruitment to the CCND1 and MYC promoters. Int J Cancer. 2015 Jun 1;136(11):2680-92. PubMed PMID: 25363551
• Finlay-Schultz J, Cittelly DM, Hendricks P, Patel P, Kabos P, Jacobsen BM, Richer JK, Sartorius CA. Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and Stat5a. Oncogene. 2015 Jul;34(28):3676-87. PubMed PMID: 25241899
• The Role of Androgen Receptors in Postmenopausal Breast Cancer Dawn R. Cochrane, Britta M. Jacobsen, Annie Jean, Anthony Elias, and Jennifer K. Richer. Department of Defense Era of Hope Meeting, April 2011.
• Cochrane DR, Jacobsen BM, Jean A, Protter AA, Elias A, Richer JK. The Role of Androgen Receptor in Postmenopausal Breast Cancer. ENDOCRINE SOCIETY ANNUAL MEETING. June 2011.
• Sikora MJ, Jacobsen BM, Levine K, Chen J, Davidson NE, Lee AV, Alexander CM, Oesterreich S. WNT4 mediates estrogen receptor signaling and endocrine resistance in invasive lobular carcinoma cell lines. Breast Cancer Res. 2016 Sep 20;18(1):92. PubMed PMID: 27650553
• D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK. Cooperative Dynamics of AR and ER Activity in Breast Cancer. Mol Cancer Res. 2016 Nov;14(11):1054-1067. PubMed PMID: 27565181
• Unliganded progesterone receptors attenuate taxane-induced breast cancer cell death by modulating the spindle assembly checkpoint. Badtke MM, Jambal P, Dye WW, Spillman MA, Post MD, Horwitz KB, Jacobsen BM. Breast Cancer Res Treat. 2012 Jan;131(1):75-87. Epub 2011 Feb 22.
• Progesterone receptors, their isoforms and progesterone regulated transcription. Jacobsen BM, Horwitz KB. Mol Cell Endocrinol. 2011 Sep 17. [Epub ahead of print]
• Jacobsen BM, Cochrane DR, Howe EN, Connaghan K, Bain DL, and Richer JK. Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Mol Cell Endocrinol. 2012 Jan 18. [Epub ahead of print]
• Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Elias AD, Richer JK. MDV3100, an Androgen Receptor Signaling Inhibitor, Inhibits Tumor Growth in Breast Cancer Preclinical Models Regardless of Estrogen Receptor Status. AACR Annual Meeting, 2012.
• Sahores A, May M, Sequeira G, Fuentes C, Jacobsen B, Lanari C, Lamb CA. Targeting FGFR with BGJ398 in breast cancer: Effect on tumor growth and metastasis. Curr Cancer Drug Targets. 2017 Dec 13. [Epub ahead of print] PubMed PMID: 29237381
• Harrell JC, Shroka TM, Jacobsen BM. Estrogen induces c-Kit and an aggressive phenotype in a model of invasive lobular breast cancer. Oncogenesis. 2017 Nov 27;6(11):2. PubMed PMID: 29176653
• Contreras-Zárate MJ, Ormond DR, Gillen AE, Hanna C, Day NL, Serkova NJ, Jacobsen BM, Edgerton SM, Thor AD, Borges VF, Lillehei KO, Graner MW, Kabos P, Cittelly DM. Development of Novel Patient-Derived Xenografts from Breast Cancer Brain Metastases. Front Oncol. 2017;7:252. PubMed PMID: 29164052
• Fabris V, Abascal MF, Giulianelli S, May M, Sequeira GR, Jacobsen B, Lombès M, Han J, Tran L, Molinolo A, Lanari C. Isoform specificity of progesterone receptor antibodies. J Pathol Clin Res. 2017 Oct;3(4):227-233. PubMed PMID: 29085663
• Finlay-Schultz J, Gillen AE, Brechbuhl HM, Ivie JJ, Matthews SB, Jacobsen BM, Bentley DL, Kabos P, Sartorius CA. Breast Cancer Suppression by Progesterone Receptors Is Mediated by Their Modulation of Estrogen Receptors and RNA Polymerase III. Cancer Res. 2017 Sep 15;77(18):4934-4946. PubMed PMID: 28729413
• Sahores A, May M, Sequeira G, Fuentes C, Jacobsen B, Lanari C, Lamb CA. Targeting FGFR with BGJ398 in breast cancer: Effect on tumor growth and metastasis. Curr Cancer Drug Targets. 2017 Dec 13. [Epub ahead of print] PubMed PMID: 29237381
• Nagle AM, Levine KM, Tasdemir N, Scott JA, Burlbaugh K, Kehm J, Katz TA, Boone DN, Jacobsen BM, Atkinson JM, Oesterreich S, Lee AV. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors. Clin Cancer Res. 2018 Oct 15;24(20):5165-5177. PubMed PMID: 29941485
• Elias A, Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Protter AA, Richer JK. MDV3100, an Androgen Receptor Signaling Inhibitor, Inhibits Tumor Growth of Estrogen and Androgen Receptor Positive (ER+/AR+) Breast Cancer Xenografts. American Society of Clinical Oncology 2012.
• Sahores A, Figueroa V, May M, Liguori M, Rubstein A, Fuentes C, Jacobsen BM, Elía A, Rojas P, Sequeira GR, Álvarez MM, González P, Gass H, Hewitt S, Molinolo A, Lanari C, Lamb CA. Increased High Molecular Weight FGF2 in Endocrine-Resistant Breast Cancer. Horm Cancer. 2018 Oct;9(5):338-348. PubMed PMID: 29956066
• Lamb CA, Fabris VT, Jacobsen B, Molinolo AA, Lanari C. Biological and clinical impact of imbalanced progesterone receptor isoform ratios in breast cancer. Endocr Relat Cancer. 2018 Jul 10. [Epub ahead of print] PubMed PMID: 29991638
• Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 Jul 25;3(14). [Epub ahead of print] PubMed PMID: 30046001
• Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Daddario-Axlund S, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. ENDOCRINE SOCIETY ANNUAL MEETING. June 2012.
• Tasdemir N, Bossart EA, Li Z, Zhu L, Sikora MJ, Levine KM, Jacobsen BM, Tseng GC, Davidson NE, Oesterreich S. Comprehensive Phenotypic Characterization of Human Invasive Lobular Carcinoma Cell Lines in 2D and 3D Cultures. Cancer Res. 2018 Nov 1;78(21):6209-6222. PubMed PMID: 30228172
• Astashchanka A, Shroka TM, Jacobsen BM. Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Res Treat. 2018 Oct 13. [Epub ahead of print] PubMed PMID: 30317423
• Cochrane DR, Jacobsen BM, Jean A, Protter AA, Elias A, Richer JK. The Role of Androgen Receptor in Postmenopausal Breast Cancer. ENDOCRINE SOCIETY ANNUAL MEETING. June 2011.
• Astashchanka A, Shroka TM, Jacobsen BM. Mucin 2 (MUC2) modulates the aggressiveness of breast cancer. Breast Cancer Res Treat. 2019 Jan;173(2):289-299. PubMed PMID: 30317423
• Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. 2019 Jun;175(2):327-337. PubMed PMID: 30798422
• Giulianelli S, Riggio M, Guillardoy T, Pérez Piñero C, Gorostiaga MA, Sequeira G, Pataccini G, Abascal MF, Toledo MF, Jacobsen BM, Guerreiro AC, Barros A, Novaro V, Monteiro FL, Amado F, Gass H, Abba M, Helguero LA, Lanari C. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERa and PRB?4 isoform to MYC regulatory sequences. Int J Cancer. 2019 Oct 1;145(7):1874-1888. PubMed PMID: 30843188
• Pinto MP, Jacobsen BM, Horwitz KB. An immunohistochemical method to study breast cancer cell subpopulations and their growth regulation by hormones in three-dimensional cultures. Front. Endocrin. 2011 2:15. doi: 10.3389/fendo.2011.00015
• Progesterone receptors, their isoforms and progesterone regulated transcription. Jacobsen BM, Horwitz KB. Mol Cell Endocrinol. 2012 Jun 24;357(1-2):18-29. doi: 10.1016/j.mce.2011.09.016. Epub 2011 Sep 17. Review. PMID: 21952082 [PubMed - indexed for MEDLINE]
• Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Cochrane DR*, Jacobsen BM*, Connaghan KD, Howe EN, Bain DL, Richer JK. *co-first authors Mol Cell Endocrinol. 2012 May 15;355(1):15-24. doi: 10.1016/j.mce.2011.12.020. Epub 2012 Jan 18. PMID: 22330642 [PubMed - indexed for MEDLINE]
• DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP. Gynecol Oncol. 2012 Oct;127(1):241-8. doi: 10.1016/j.ygyno.2012.06.017. Epub 2012 Jun 16. PMID: 22710073 [PubMed - in process]
• Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4. Cittelly DM, Finlay-Schultz J, Howe EN, Spoelstra NS, Axlund SD, Hendricks P, Jacobsen BM, Sartorius CA, Richer JK. Oncogene. 2012 Jul 2. doi: 10.1038/onc.2012.275. [Epub ahead of print] PMID: 22751119 [PubMed - as supplied by publisher]
• Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxel. Schlaepfer IR, Hitz CA, Gijón MA, Bergman BC, Eckel RH, Jacobsen BM. Mol Cell Endocrinol. 2012 Nov 5;363(1-2):111-21. doi: 10.1016/j.mce.2012.08.005. Epub 2012 Aug 16. PMID: 22922095 [PubMed - in process]
• Estrogen switches pure mucinous breast cancer to invasive lobular carcinoma with mucinous features. Jambal P, Badtke MM, Harrell JC, Borges VF, Post MD, Sollender GE, Spillman MA, Horwitz KB, Jacobsen BM. Breast Cancer Res Treat. 2013 Jan;137(2):431-48. doi: 10.1007/s10549-012-2377-x. Epub 2012 Dec 18. PMID: 23247610 [PubMed - in process]
• Genomic Signatures of Pregnancy-Associated Breast Cancer Epithelia and Stroma and their Regulation by Estrogens and Progesterone. Harvell DME, Kim J, O’Brien J, Tan AC, Borges VF, Schedin P, Jacobsen BM, Horwitz KB. 2013. Accepted to Hormones and Cancer
• Preliminary Data from a Phase I Study Evaluating Enzalutamide in Patients with Incurable Breast Cancer. Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Jean A, Guerrero J, G?mez F, Medicherla S, Jedlicka P, Torkko KC, Elias AD, Protter AA, Richer JK. 2012. San Antonio Breast Cancer Symposium
• MDV3100, an Androgen Receptor Signaling Inhibitor, Inhibits Tumor Growth in Breast Cancer Preclinical Models Regardless of Estrogen Receptor Status. Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Bernales S, Protter AA, Elias AD, Richer JK. 2012. Annual Meeting of the Amercian Association of Cancer Research.
• Effect of Enzalutamide (formerly MDV3100), an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts Elias A, Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Protter AA, Richer JK. 2012. Annual Meeting of the American Society of Clinical Oncology (ASCO).
• MDV3100, an Androgen Receptor Signaling Inhibitor, Abrogates Androgen- and Estrogen-Mediated Breast Cancer Xenograft Tumor Growth. Cochrane DR, Jacobsen BM, Cittelly DM, Howe EN, Jean A, Spoelstra NS, Protter AA, Elias AD, Richer JK. 2012. Keystone Symposia on Nuclear Receptor Matrix: Reloaded
• Elucidating the Role of AR in Breast Cancer. D’Amato NC, Gu H, Cochrane DR, Bernales S, Jacobsen BM, Jedlicka P, Torkko KC, Edgerton SM, Thor AD, Elias AD, Protter AA, Richer JK. Annual meeting of the American Association of Cancer Research.
• Malignant stroma regulates Luminal breast cancer-cell growth vs. Basal breast cancer cell migration through different growth factor pathways Pinto MP, Jacobsen BM, Horwitz KB. Annual meeting of the American Association of Cancer Research.
• Progestin gene regulation in dual PR/AR positive breast tumors. Finlay-Schultz JA, Hendricks P, Rosen RB, Flory K, Elias A, Jacobsen BM, Kabos P, Sartorius CA. Annual meeting of The Endocrine Society.